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Purpose:  The UK Government-funded National Health Service (NHS) is experiencing 
significant pressures owing to the complexity of challenges to, and demands of, 
healthcare provision. This situation has driven government policy level support for 
transformational change initiatives, such as Value-Based Health Care (VBHC), through 
closer alignment and collaboration across the healthcare system-life science sector nexus.  
 
The purpose of this paper is to evaluate the necessary antecedents to collaboration in 
VBHC through a critical exploration of the existing literature, with a view to establishing 
the foundations for further development of policy, practice and theory in this field 
 
Design/methodology/approach:  A literature review was conducted via searches on 
Scopus and Google Scholar between 2009-2019 for peer-reviewed articles containing 
keywords and phrases ‘Value-based healthcare industry’ and ‘healthcare industry 
collaboration’. Refinement of the results led to the identification of ‘guiding conditions’ 
for collaboration in VBHC. 
 
Findings:  Five literature-derived guiding conditions (GCs) were identified as necessary 
for the successful implementation of initiatives such as VBHC through system-sector 
collaboration. These are: a multi-disciplinarity; use of appropriate technological 
infrastructure; capturing meaningful metrics; understanding the total cycle-of-care; 
financial flexibility. The paper outlines research opportunities to empirically test the 
relevance of the five GCs with regard to improving system-sector collaboration on 
VBHC. 
 




Originality/value:  The paper has developed a practical and constructive framework that 
has the potential to inform both policy and further theoretical development on collaboration 
in VBHC. 
 
Keywords: Healthcare, Government, Management, Process, VBHC, Innovation, Life 
Science Sector, Organization, Industry, Policy, NHS.  
 





The National Health Service (NHS) in the UK, in common with other national healthcare 
systems, is facing significant challenges in managing the demands associated with an aging 
population with increasingly complex needs, higher workforce and technology costs, and 
financial constraints (Pilemalm, Lindgren, & Ramsell, 2016). Despite increasing 
government investment in recent years, projected demands continue to outstrip the 
resources available to meet them (The Kings Fund, 2019).  It should additionally be noted 
that the NHS is significantly devolved to regional authorities and semi-autonomous local 
trusts, with complex mechanisms of regulation and funding (Crocker, Johnson, & King, 
2009). 
 
Under such conditions, optimisation of service delivery with constrained resources and 
adherence to performance measures requires a careful balance (Chahal & Eldabi, 2011). 
The possibility and efficiency of the 'healthcare and life science collaboration' are a 
function of the existing regulatory frameworks and an overall logic that drives a 
government's scope and modes of involvement in the economy.  As such, the examination 
of the healthcare-life science nexus, as exemplified by government-funded NHS and 
private sector, offers a useful insight into the issues and relationships between healthcare 
external organisations (Ferlie & McGivern, 2003). Since then Government policy 
documents have recognised that closer alignment between healthcare system and private 
life science sector companies is required to stem the growing challenges of healthcare 
provision (Gov UK (OLS), 2017; Gov UK, 2017; WAG, 2018). One approach which is 
gathering momentum is Value-Based Health Care (VBHC); a mechanism through which 
it is theoretically possible to by provide better value personal, social, technical, and 
allocative value in healthcare provision for the resource spent (EXPH, 2019; M. Gray, 
2017a). 
 
The overarching objective of this paper is to explore and evaluate the necessary antecedents 
for system-sector collaboration with a view of establishing foundations for the future 
development of policy, practise and theory in the field of VBHC. As part of this study this 
paper examines the concept of VBHC as a potential means of addressing these complex 
challenges in the UK context, with particular consideration given to the importance of 
collaboration between the healthcare system and the life-sciences sector.  One of the aims 
of the study is to explore the varying definitions of VBHC, and consequently a definition 
is not offered as a foundation in this introduction.  However, VBHC could essentially be 
described as focusing on the investment of resources where they are most likely to deliver 




The next section of the paper therefore traces the development of VBHC from the work of 
(among others) Porter and Teisberg (2004; 2006) in the United States (US). In addition, 
the emerging understanding of VBHC is explored from a European and UK perspective.  
This section also explores the complex UK context that is arguably driving the need for 
VBHC, as well as introducing the importance of collaboration between the healthcare 
system and the life-sciences sector. 
 
Following this, the methodology of the study is briefly set out, before the main findings of 
the paper are presented and discussed.  The study reviewed the literature on VBHC and 
has identified five key ‘guiding conditions’ which are hypothesised as critical success 
factors in the implementation of VBHC through collaboration between the healthcare 
system (henceforth ‘system’) and the life science sector (henceforth ‘sector’). 
 
The overall objective and purpose of this paper is to evaluate the necessary antecedents to 
collaboration in VBHC In doing so we make three main contributions Firstly, the paper 
evaluates the concept of VBHC from a specifically UK perspective, relating it to this 
context and proposing a nuanced characterisation to augment the US-based origins of 
VBHC.  Secondly, the study surfaces those high-level guiding conditions necessary for 
successful system-sector collaboration.  Finally, a research agenda is proposed that offers 
prospects for further contributions to policy, practice and theory in VBHC. Critical 
exploration of the existing literature in this study sets foundations for development of 
practical and constructive framework through empirical research. 
 
Before proceeding to a more detailed exploration of VBHC in the next section, it is 
important to be clear what is meant by both ‘healthcare system’ and ‘life sciences sector’ 
in this paper.  A ‘healthcare system’ has been defined by World Health Organisation 
(WHO) as all the activities whose primary purpose is to promote, restore or maintain health 
(WHO, 2009).  This includes both the physical infrastructure, processes and systems 
involved in providing a range of services to patients, and the health workforce or healthcare 
providers concerned with delivering outcomes to patients.  The life sciences sector in this 
paper refers to the biopharmaceutical and medical technology companies involved in 
medicine development and areas such as genetics-based and personalised healthcare, social 
media technologies, information and communications technologies, data science and 




Defining value-based healthcare 
 
The concept of VBHC is generally considered to have originated through the work of 
Michael Porter and Elizabeth Teisberg at Harvard Business School at the start of this 
century (Porter and Teisberg, 2004).  They argued that the (then) current state of 
competition in US Healthcare was a source of value destruction, or at least zero-sum 
outcomes, rather than creating value for patients (Porter and Teisberg, 2004).  This work 
formed the basis of a subsequent book (Porter and Teisberg, 2006) which emphasised the 
language of ‘value’ more than in earlier work, hence the contemporary label, ‘Value-Based 
Healthcare’.  Porter is of course very closely associated with the notion of ‘value’ from his 
work on value chains and value systems in the field of strategy, through to later 





The original definition of VBHC proposed by Porter and Teisberg (2006), has gained 
traction: 
 
“Patient value is defined as patient-relevant outcomes, divided by the costs per 
patient across the full cycle of care in order to achieve these outcomes. Value-
Based Healthcare focuses on maximising the value of care for patients and 
reducing the cost of healthcare.” 
      (Porter and Teisberg, 2006) 
This was further discussed by Porter and Lee (2013) emphasising the key objective for 
providers of healthcare organisations: 
 
“In health care, the overarching goal for providers, as well as for every other 
stakeholder, must be improving value for patients, where value is defined as 
the health outcomes achieved that matter to patients relative to the cost of 
achieving those outcomes.”   
(Porter and Lee, 2013, p.4) 
 
The US-based literature, which is largely derived from Porter and his collaborators, focuses 
on cost-restraint objectives and tackling allocative efficiency, productive efficiency and 
outcome-based contracting.  There are variations on the definition of VBHC, but the 
dominant theme remains the shift from supply-driven systems orchestrated around clinical 
activity, towards a patient-driven system where provider-defined outcomes or quality 
indicators are delivered to patients and are costed to derive ‘value’. 
 
Porter’s work is based in the US context, while the European view of VBHC is arguably a 
broader interpretation extending beyond individual patient value to consider societal 
impact, available resource and equitable distribution.  See for example the following 
definition from The European Commission Expert Panel on Effective Ways of Investing 
in Health (EXPH):  
 
‘…a comprehensive concept built on four value-pillars: appropriate care to 
achieve patients’ personal goals (personal value), achievement of best possible 
outcomes with available resources (technical value), equitable resource 
distribution across all patient groups (allocative value) and contribution of 
healthcare to social participation and connectedness (societal value).’ 
(EXPH, 2019, p.5) 
 
While acknowledging that different stakeholders will potentially have different 
perceptions of how value is defined, they also stated that: 
 
“…value-based health systems are seen by some as a system change which could 
improve the quality of healthcare for patients, while simultaneously making 
healthcare more cost-effective.” 
        (EXPH, 2019, p. 9) 
 
The next sub-section now explores the context within which VBHC is beginning to be 
implemented, highlighting the strategic drivers for VBHC and thereby arguing for the 




Value-based health care: Context and drivers for collaboration. 
 
A complex and interwoven array of economic, political, technological and demographic 
change-drivers impact on both healthcare systems and the life sciences sector in the UK 
and beyond (Deloitte, 2018). 
 
Economically, the evolving situation is concerning for the UK government and decision 
makers at devolved governments who decide how they wish to fund their healthcare 
system. Global spending growth on healthcare increased at an annual rate of 1.3% from 
2012-2016 rising to a projected 4.1% between 2017 and 2021 (Deloitte, 2018).  The 
increase is driven by factors including ageing population, increasing population, advances 
in medical treatments, and rising labour cost (EIU, 2016a). In the UK, healthcare spending 
has increased at a faster rate than inflation and GDP, accounting for 7.3% of national 
income in year 2018/19 (Charlesworth et al., 2018). Increased spending by NHS England 
is projected to increase by an average of 3.3% a year between 2018-19 and 2033-34, 
translating to a real-term increase in spending from £128 billion to £210 billion 
(Charlesworth et al., 2018).  
 
Despite such expenditure, efficiencies are hard to derive (Berwick & Hackbarth, 2012).  
The OECD report on “Wasteful Spending in Health” (OECD, 2017) presented data on 
inappropriate care and wasted resources with estimations ranging from a conservative 10% 
up to 34% of expenditure. 
 
Politically, the challenges facing healthcare systems in the UK has been noted at a national 
(Gov UK, 2017) and devolved Government (WAG, 2018) level.  There is growing 
recognition of active NHS engagement with stakeholders and organisations in the life 
science sector, to enable transformation in the way UK healthcare is delivered (Gov UK, 
2017). This is accompanied by a policy drive towards more effective system-sector 
collaboration as a mechanism by which it is possible to address the mounting healthcare 
challenges through adoption and implementation of VBHC.  
 
Technologically, research, development and adoption are driving a paradigm shift towards 
delivering patient experience improvements.  (Charlesworth,  Watt, & Johnson, 2018). The 
annual spend on R&D in the English NHS, inclusive of that spent through National 
Institute for Health Research (NIHR) totalled £1.2bn between the years 2014 and 2015; 
and the approximate annual spend on facilitating the adoption and spread of innovation in 
the NHS through Academic Health Science Networks (AHSNs) was £50m between 2013 
and 2018 (Charlesworth et al., 2018). 
Economic pressure and growing demand from patients lead to policymakers exploring 
alternative means to manage healthcare budgets (EIU,  2016b).  This coupled with the 
challenges to continue to adopt innovation in medicines and services provided by the NHS 
requires a step-change towards moving from volume to value in delivering sustainable 
healthcare. 
 
These various drivers, of which these are a sample, are leading to increased emphasis on 




“We’ve got to break down barriers and build long-term, focussed, 
collaborative relationships where our incentives are aligned, so if you win, we 
win; if you lose, we lose.” 
                                                    (Porter & Ishrak, 2015, p. 6) 
“There are a lot of opportunities for reduced costs, and I think medical 
technology companies can play a big role” 
                                                    (Porter & Ishrak, 2015, p. 4) 
 ‘The historical model where innovators simply throw new products at health 
systems and allow them to layer these into existing pathways is no longer 
viable.’   
                                           Professor Sir John Bell (Gov UK, 2016, p. 7). 
 
Policy makers have begun to respond to these strategic pressures to seek closer system-
sector alignment to reward the sector for delivery of outcomes to patients.  Initiatives such 
as value-based and ‘Prudent’ healthcare are highlighted in both the UK Life Sciences 
Strategy (Gov UK, 2017) and A Healthier Wales (WAG, 2018) respectively, both alluding 
to system-sector collaboration.  Proposed areas for collaboration include: 
 
(1) Risk-sharing with respect to development of tools and therapies using NHS 
infrastructure to run iterative evaluation studies with the aim of benefit sharing 
from proven technologies; 
(2) collaborative re-shaping clinical pathways to improve efficiencies and patient 
throughput activity;  
(3) Collection of real-world data and linking this to assess clinical and cost-
effectiveness  
(Gov UK, 2018a). 
 
While collaboration arguably remains sporadic and fragmented, there are a number of 
instances of fruitful system-sector collaboration.  For example, AstraZeneca and Leeds 
Teaching Hospital engaged in a partnership focused on  reviewing heart disease patients’ 
medication, leading to a fall in acute coronary syndrome readmissions by approximately 
50% (AstraZeneca, 2018).  A further example is the work of Medtronic Integrated Health 
Solutions partnering with a range of NHS hospital trusts in England to provide and manage 
catheterisation laboratories, resulting in significant operational efficiencies (Deloitte, 
2019).  
 
This section has introduced the concept of VBHC and traced its development form its US 
origins to the beginnings of implementation in the UK context today.  The argument has 
been presented that the adoption of system-sector collaboration for VBHC can lead to 
fundamental transformation to improve healthcare delivery through investing in best value 
for the population (allocative efficiency); ensuring the best value in clinical pathways 
(productive efficiency); and deliver the best value when procuring services, medical 
devices and medicines (outcome-based contracting).  The paper now moves on to briefly 






The research design for this paper was based on a structured literature search and an 
iterative content analysis.  The literature included peer reviewed journal articles as well as 
government reports and policy statements and so on. 
 
The initial literature search was conducted through the Scopus Catalogue up to 2019, 
seeking peer reviewed articles, using key words “value-based healthcare industry drugs 
medications”; “Value-based Healthcare Industry Healthcare Collaboration”; 
“collaboration Value-based Healthcare”.  This initial search generated over 8,900 articles. 
 
These articles were reviewed manually for the 200 most relevant based on titles of the 
articles and the abstracts.   
 
Based on a methodology for identifying factors from extant literature used by Bacon, 
Williams, & Davies, 2019 a total of 63 of these articles were reviewed in detail.  Any 
guiding condition for the successful collaborative implementation of VBHC found in more 
than ten of these articles was included for further exploration. 
 
The authors then used the same key words in public search engines such as ‘Google’.  This 
was used alongside references from the 200 papers to identify relevant literature and 
reports from Government and consultant groups, online reports, articles and case studies 
relevant to the implementation of VBHC and system-sector collaboration.   Relevance was 
determined by iterative manual viewing of literature content and it being inclusive of 
contextual information surrounding system and sector collaboration.   
 
Used jointly, these methods of data collection and analysis allowed multiple perspectives 
to be gleaned on the implementation of VBHC with particular emphasis on collaboration 
between elements of the healthcare system and the life sciences sector.  The next section 




Guiding conditions for system-sector collaboration for implementation of in value-
based health care  
 
One of the main contributions of this paper lies in identifying which conditions are 
proposed to be significant conditions to facilitate successful system-sector collaboration in 
VBHC.  The resulting guiding conditions, their general characteristics derived from the 
















Collaboration between all stakeholders; Multi-
disciplinary; organization from across the System, 
patients, patient advocates and private sector; a 
team-in-lead strategy; public-private partnerships; 
spectrum of healthcare providers; multi-sector 
engagement; integrated care delivery systems; 
collaboration with physicians, hospital systems; 
work together and to each-others strengths; all 
stakeholders to engage with medical device 
industry; new relationships with industry 
(Hara et al., 2003); (VBHC Center Europe, 2019); 
(Horne et al., 2019); (Malik et al., 2018); (Nishtar, 
2004); (Porter et al., 2013); (Beck et al., 2012); 
(Kaplan & Babad, 2011); (Zelmer, 2018); (Nilsson 
et al., 2017); (Gerecke et al., 2015); (Dafny et al., 
2016); (Porter & Ishrak, 2015); (Medtronic, 2016); 
(Gov UK, 2016); (Martschinke & Traut, 2016); (Hu 
et al., 2000); (WAG, 2018); (EIU, 2016b); (Young 
et al., 2001); (Hurh, Ko, & Lee, 2017); (Handke et 




Most appropriate feasible measures; ICHOM set; 
Patient Reported Outcomes PROMS; measure 
quality and cost indicators across full  care cycle 
of patient care; provide real-time data; connect 
and analyse accurate quality and financial data; 
costing and informatics expertise; patient’s 
outcome and true cost, performance measurement; 
public reporting of quality measures; analyse 
outcomes and costs holistically; total costs of 
patient’s medical condition; consensus-based 
patient-centric outcome measures. 
(VBHC Center Europe, 2019); (Chapman, 2014); 
(ICHOM, 2015); (Lee, 2010) ; (Porter et al., 2013); 
(Beck et al., 2012); (Aneurin Bevan University 
Health Board, 2019); (Kavanagh et al., 2012); 
(Porter & Lee, 2013); (Handke et al., 2017); (Porter 
& Ishrak, 2015); (Neumann et al., 2011); (Wang et 
al., 2009); (Doyle, 2011); (Martschinke & Traut, 
2016); (Miller, 2012); (Nilsson et al., 2017); (WAG, 









Infrastructure; Technologies; solving the data 
extraction gap; effective health information 
system; patient-centred mobile infrastructure; 
telepresence technology; build and enable 
information technology platforms; digital 
infrastructure to capture information; technology 
systems; health data infrastructure    
(Hara et al., 2003); (Patel, Pettitt, & Wilson, 2012); 
(Deloitte, 2018); (VBHC Center Europe, 2019); 
(Nishtar, 2004); (Chapman, 2014); (Beck et al., 
2012); (Porter & Ishrak, 2015); (Gov UK, 2016); 
(Kotzbauer & Weeks, 2015); (Neumann et al., 2011) 
; (Carlson et al., 2010); (Ford & Hughes, 2007); 
(EIU, 2016b); (Hurh et al., 2017). 
Knowledge of 
the Total 
Cycle of Care  
Whole cycle of patients care; full cycle of care; 
total life-cycle; complete cycle of care; full care 
pathway; quality cycle affecting whole system 
pathways; entire care continuum; complete 
pathway of disease. 
(Kaplan & Porter, 2011); (ICHOM, 2015); 
(Moxham, 2018); (Porter et al., 2013); (Porter & 
Lee, 2013); (Gerecke et al., 2015); (Keel et al., 
2017); (WAG, 2018);  (Deerberg-Wittram et al., 
2017); (Verbeek & Lord, 2007). 
Financial 
Flexibility 
Bundle Payments for Care Improvements (BPCI); 
adequate resources (finance, time, physical space, 
equipment, tools and personnel); flexibility; 
contract and risk management; new business 
models that align financial incentives; modify 
financial model to bundle reimbursement; access 
to required capital finance; value-based 
purchasing; new financial models; risk-sharing 
agreements to link payment for drugs to health 
outcomes; flexible reimbursement system; in-
flexible cost-based reimbursements is a barrier; 
performance-based reimbursement schemes; data 
informed investment/disinvestment. 
(Hardin et al, 2017); (Mills & Kanavos, 2019); 
(EIU, 2016b); (Gerecke et al, 2015); (Robinson et 
al, 2018); (Lewis, 2019); (Eggbeer et al, 2015); 
(Carlson et al., 2010); (Garrison & Towse, 2017); 
(Neumann et al., 2011); (Damberg et al., 2014); 
(Haywood, 2010); (Kotzbauer & Weeks, 2015); 
(Deerberg-Wittram et al., 2017); (Porter & Ishrak, 
2015); (Porter et al., 2013); (Lee, 2010); (Field & 






The following sections of the paper now describe and discuss the five GCs identified in 
the literature review as shown in Table 1.     
 
One: A multidisciplinary approach 
 
The literature describes the need for collaboration between stakeholders for the 
implementation of VBHC through system-sector partnerships as imperative (Deloitte, 
2019; Gov UK, 2017; Nishtar, 2004). A common thread throughout are improvements to 
the ‘Value’ of healthcare provision by healthcare providers (e.g. hospitals) and associated 
personnel (e.g. clinical and non-clinical staff) is not established without collaboration and 
the involvement of all relevant stakeholders along a service user’s (i.e. patient’s) pathway 
of care (Beck et al., 2012; EIU, 2016b; Gov UK, 2016; Handke et al., 2017; Horne et al., 
2019; Medtronic, 2016; VBHC Center Europe, 2019; Young et al., 2001).    
 
It is argued that collaborative improvements in healthcare provision via a multi-
disciplinary approach includes the cross-pollination of perspectives from internal system 
stakeholders as well as those outside the system, including those from the sector (e.g. 
pharmaceutical and MedTech companies), charities (Gov UK, 2017; WAG, 2018), 
academia (VBHC Center Europe, 2019), patients and patient advocates (Horne et al., 
2019). It is argued in this literature that improvements to healthcare provision can be 
realised by identifying meaningful outcomes. Providers aiming to improved healthcare 
provision, delivery and patient outcomes can do so through increased efficiency and quality 
of care. This is inherently complex and will require leveraging of pre-requisite multi-level 
knowledge, skills, experience and specialist expertise ( Gov UK, 2017; Neville, 2019; 
WAG, 2018. These elements are routinely utilised in areas of service provision in the 
system and can be used to compliment elements from sector stakeholders who offer 
innovation, new medicines and technologies (Gov UK: Office For Life Sciences (OLS), 
2017;  Neville, 2019; WAG, 2018) to support VBHC implementation through multi-
disciplinary collaboration.   
 
Malik et al., 2018 demonstrate that a multi-disciplinary approach is a preferential option 
as opposed to a siloed approach when attempting to deliver VBHC. The study showed that 
a ‘Physicians in the Lead’ (PIL) strategy engages physicians in system organisations’ 
processes to make them responsible for the quality and efficiency of their departments 
healthcare provision. This aligns the aim of delivering effective, efficient and cost-effective 
care with Porter’s definition of ‘value’ in VBHC as ‘patient health outcomes per dollar 
spent’. This study found that the holistic outcome and care delivery requires a teamwork-
based strategy owing to the complementary skills and training of various healthcare 
professionals.  This is because not all levels of specialisms and skill levels are required to 
deliver all outputs and outcomes throughout a service users’ journey through healthcare 
provider or system – and therefore some tasks can be delegated. As such a new strategy 
was proposed, namely a “team in lead” strategy (Malik et al., 2018).  
 
A variety of government publications (Gov UK, 2017, 2018a, 2018b; WAG, 2018) and 
other literature (Handke et al., 2017; Kaplan & Babad, 2011) indicate a strong advocacy 
for a multi-disciplinary approach and closer system-sector alignment for more efficient 
implementation of VBHC initiatives. Further publications allude to the requirement for 
support from academic institutions (Gov UK, 2016, 2017; VBHC Center Europe, 2019; 
WAG, 2018); Government (EIU, 2016b; Gov UK: Office For Life Sciences (OLS), 2017; 
Gov UK, 2016; R. M. Kaplan & Babad, 2011; WAG, 2018); and seekers of healthcare 
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services (i.e. patients) (Beck et al., 2012; Handke et al., 2017; Medtronic, 2016; Porter et 
al., 2013). 
 
It should be borne in mind that in the USA, the VBHC approach is seen as a vehicle to 
increase market share or drive profits through outcome improvement. Some studies 
describe this version of VBHC as driving performance through competition and increasing 
the sectors customer base (i.e. healthcare providers) (Porter & Teisberg, 2006) which 
results in fragmentation and variation in the quality of care provision by healthcare 
providers, as these efforts do not take value at a population level into consideration (Lewis, 
2019). In a publicly funded system, such as the NHS in the UK, which has the need to 
integrate patient care to achieve best possible outcomes and experience, it is arguably about 
delivering the right care, at the right time, with decisions being made based on service-user 
feedback, which appears to be more aligned with European and UK systems (European 
Commission, 2019). This approach to VBHC implementation takes the population level 
perspective on VBHC delivery and therefore takes patients input into a multi-disciplinary 
approach as intrinsic to the development and implementation of VBHC in such systems 
(Lewis, 2019). 
 
However, it can be argued that a multi-disciplinary system-sector collaboration around 
VBHC can bring all necessary disciplines to the table and act as a vehicle for appraising 
new evidence from data capture during implementation of new medical technologies, 
pharmaceuticals and other sector products to inform an investment or dis-investment 
strategies according to outcomes which matter to healthcare providers and seekers. 
 
In seeking an industry perspective, Handke et al (2017) emphasise the need for collective 
commitment including Government inclusion to support facilitating the transition to 
VBHC (Handke et al., 2017). Government policy and resource investments focused on 
bringing system and sector together builds confidence according to the Welsh Government 
(Gov UK, 2017; WAG, 2018).  As system and sector partnerships require leaders from 
different organisations to align, the focus needs to be on achieving better outcomes for 
patients. There are many barriers; what is needed is greater respect, understanding and 
appreciation for the benefits, resources, capabilities and know-how each individual partner 
can contribute to establish successful initiatives such as VBHC (Martschinke & Traut, 
2016).  
 
Two: Meaningful metrics and measurements 
 
The challenges of determining the impact of health interventions rely on the ability to align 
on health outcomes that matter to patients and not to become focused on a single outcome 
(Porter & Lee, 2013). It also requires the value outcome measures and costs to be analysed 
across the entire cycle of care (Porter & Ishrak, 2015) which in turn requires a greater 
understanding of the total care cycle to design the approach at the outset.  
 
Although healthcare systems have been gathering data for many years much of this has 
been focused on activity and inputs not outcome: the inability to effectively measure 
outcomes becomes a barrier to adoption (Neumann et al., 2011). In a study of the lack of 
information on relative effectiveness of different treatments in mental health, Wang et al. 
identified that payers are uncertain of value of investment, which may deter adoption of  
new innovations to address unmet need (Wang et al., 2009). Thus, determining and 
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aligning on the outcome metrics is critical to achieving Value-Based Health Care (Kings 
Healthcare Partners (Gabriel et al., 2018)). 
 
In the context of the current VBHC literature, it can be seen throughout that the ability to 
capture and analyse quality and outcomes metrics, which are considered important to 
healthcare providers and service users, across the patient’s total (or full) cycle of care 
pathway is perceived to be gold standard (ICHOM, 2015; Porter & Ishrak, 2015) . The 
ability to collect and subsequently analyse metrics and measurements across the full patient 
pathway is multi-faceted.  
 
Firstly, collection of cost metrics and measurements across a care pathway enables the 
calculation of ‘total cost’ of treatment for a patient, or population of patients, and provide 
a metric for quality and outcomes provided across the pathway of care thus allowing us to 
gauge performance and healthcare provision efficiencies (Beck et al., 2012; Lee, 2010).  
 
Secondly, by capture and analysis of meaningful metrics and measurement, a baseline for 
health outcomes and costs accumulated in providing outcomes can be provided.  It should 
consequently be possible to benchmark current efficiencies and provide evidence for 
improvement or detriment on efficiencies upon implementation of new drugs, innovations 
or technologies into the patients cycle of care. This data collection and analysis of 
performance monitoring can inform business intelligence (Lee, 2010) in new VBHC 
collaborations between the system and sector and act as a mechanism to  risk management  
in risk-sharing agreements and decision making. (Lee, 2010; Neumann et al., 2011). The 
capture and analysis of metrics and measurements would be considered important to 
system-sector collaborations which are engaged in risk-sharing agreements linked with 
‘pay for performance’, or ‘pay for drug outcomes’ re-imbursement models (Doyle, 2011; 
Neumann et al., 2011).  
 
For effective capture and analysis of meaningful metrics and measurements a robust 
infrastructure or technology platform will need to be embedded in the pathway for 
monitoring. The integration of meaningful metrics and measurements with a technology 
infrastructure capable of relaying desired metrics can aid in implementation of VBHC 
initiatives by informing consensus-based, patient centric outcome measurements (Handke 
et al., 2017). Organisations such as the International Consortium for Health Outcome 
Measurements (ICHOM) is attempting to unlock the potential of VBHC by defining Global 
Standard Sets of outcome measures that matter most to patients and driving adoption and 
reporting these measures worldwide to create better value for all stakeholders (Chapman, 
2014; ICHOM, 2015). 
 
For these reasons it is proposed that meaningful metrics and measurements are an 
important guiding condition for the successful implementation of VBHC through a system-
sector collaboration as they can contribute to informed decision making, quality 
improvement and cost reduction in VBHC provision.  
 
Three: Robust infrastructure and technological platforms 
 
The next emerging guiding condition from the reviewed literature as essential for 




VBHC requires a scalable platform to manage the data, to allow operationalisation, 
management and evaluation. Porter cites this infrastructure as a key requirement for 
adoption (Porter & Ishrak, 2015). Limitations in, or the complete absence of, an adequate 
information system or technology to capture outcomes at scale often is identified as the 
barrier to success (Ford & Hughes, 2007; Kotzbauer & Weeks, 2015b; Neumann et al., 
2011).  
 
As part of UK Government report (Gov UK, 2016) seeking to support accelerated uptake 
to innovation and outcomes, an identified priority is that the digital infrastructure should 
enable the system to capture information on the use of innovations and associated 
outcomes, proposing that: 
 
“Systems that collect electronic information on prescribing, procurement, 
dispensing, pricing and outcomes will be essential in enabling improvements to 
patient care.” 
                                                                                       (ARR, Gov UK, 2016, p.45) 
 
As described, it appears that a robust technology platform or infrastructure which has the 
capability for collecting the appropriate data and information is imperative (Handke et al., 
2017). The integration of data capture and analysis through a technology platform or 
infrastructure should be intuitive, allowing users of the technology (healthcare providers 
or users) to make decisions based on meaningful metrics and measurements.  
 
Moreover, to be effective, the technology platform/infrastructure must be robust enough to 
be embedded within normal social and organisational practises to be effective (Hara et al., 
2003). In the context of VBHC effective healthcare system infrastructures are required for 
closed system data sharing which could be used to ensure common understanding among 
partnering stakeholders (Chapman, 2014; Nishtar, 2004). The importance of a robust 
technology infrastructure is exemplified in the work of Kotzbauer & Weeks (2015b), where 
a lack of organisational competency to upgrade technology system, constituted a barrier to 
the implementation of VBHC payment systems, a finding which resonates with those of 
others (see for example Ford & Hughes, 2007; Neumann et al., 2011). It is apparent that 
the presence of a robust technology platform or infrastructure is important, as its absence 
is frequently cited as a barrier to value-based outcomes agreements (Ford & Hughes, 2007; 
Hurh et al., 2017; Kotzbauer & Weeks, 2015b; Porter & Ishrak, 2015).  
 
There is a clear link in the literature with the previous guiding condition.  The ability to 
utilise technology platforms to capture meaningful metrics is required to support VBHC 
initiatives such as bundle payments across critical pathways.  A further example is the 
importance of the monitoring of data as evidence in risk-sharing payment for outcomes 
agreements (Carlson et al., 2010; Hurh et al., 2017; Neumann et al., 2011). It has been 
identified that there is room for improvement of health data infrastructure in most countries 
(EIU, 2016b), and this presents a challenge to VBHC initiatives which rely on capture and 
analysis of metrics and measurements to make clinical decisions or payments. In light of 
this, it is evident that a robust technology platform or infrastructure is a key guiding 






Four: Knowledge of the total cycle of care 
 
Understanding and improving the complete pathway of diseases and their treatments is 
central to determining the best outcomes for patients with the resources available 
(Moxham, 2018). To align and collaborate successfully therefore requires both system and 
sector stakeholders to understand the total cycle of care.  
 
Sackmann & Kuchenreuther (2015) identified the need for pharmaceutical companies to 
demonstrate that a medicine decreases mortality or morbidity, makes the pathway more 
efficient or reduces the resources that a patient consumes. A demonstration of pathway 
efficiency or resource efficiency relies on a robust understanding of the existing pathway; 
this also has the benefit of further supporting the implementation of innovations in 
considering the skills, services and settings required to realise the full value 
(Kuchenreuther & Sackman, 2015).  This position is also supported by Porter: 
 
“Outcomes should be measured for each medical condition covering the full 
cycle of care, including acute care, related complications, rehabilitation, and 
reoccurrences. It is the overall results that matter, not the outcome of an 
individual intervention or specialty (too narrow), or a single visit or care 
episode (too short).” 
(Porter 2010, p2) 
 
The ability to describe the existing care pathway, and its respective components, confers 
several benefits.  Organisations can assess the capabilities staff require to manage care, 
evaluate costs of each aspect of the pathway, and consider dependencies and sequencing 
of care through the pathway.  In relation to exploring the introduction of new innovations, 
organisations can evaluate how the introduction of different interventions may optimise or 
compound the pathway. This in turn allows the development of value-based outcomes 
identified through a robust understanding of the total cycle of care.  
 
Knowledge of a total cycle of care (TCC) for a specific disease can help us understand the 
current status, map that care pathway and identify areas which can be improved to drive 
better healthcare provision for the given medical condition (Verbeek & Lord, 2007). 
Furthermore, such understanding may facilitate the identification of key milestones along 
a patient’s pathway for optimal acquisition of metrics and measurements to inform clinical 
or non-clinical decision making. That is to measure the cost of providing services to the 
service user across the whole cycle of care (Porter & Ishrak, 2015; Verbeek & Lord, 2007). 
It appears that to increase ‘value’ of care provision, in other words to deliver the best 
possible outcomes with the available resource, an understanding of, and subsequent 
improvement to, the completed pathway of the disease and its treatment is a requirement 
(Moxham, 2018). Improvements to a pathway should be informed by a holistic input from 
all relevant clinical and non-clinical personnel who deliver tasks relating to healthcare 
provision across that care pathway (Gerecke et al., 2015; Porter & Lee, 2013; Porter et al., 
2013; WAG, 2018).  
 
By deriving the total cost of care provision across a given total patient pathway or TCC, 
this can be used as a baseline to trial interventions in a pathway to gauge whether there is 
a beneficial (or disadvantageous) result with respect to cost efficiencies and care provision. 
In an example of bundled payments for reimbursement, knowledge of TCC means 
providers can be held accountable across the full cycle of care. The ability for providers to 
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compare health outcomes and costs across the entire care cycle is expected to foster 
improvement through competition on value, as defined by health outcomes achieved per 
unit cost (Akerman & Stowell, 2015; ICHOM, 2015; Porter & Teisberg, 2006). There is 
currently great interest in VBHC, mostly directed at identifying which health outcomes are 
appropriate to measure for a medical condition (Keel et al., 2017). 
 
It is understood that as healthcare providers and personnel have complementary skill sets 
which dovetail to complement the patient (service users) journey throughout the TCC. 
Each staff member plays a part in the continuum of care as they possess a variety of skills 
and knowledge to execute tasks at the correct time and at the appropriate step in the patient 
pathway. Thus, it is important that each relevant stakeholder along the care pathway are 
consulted, otherwise there is a risk that implementation of a change perceived to be 
beneficial in one step of a pathway might non-beneficial results up or down-stream in the 
system.  
 
Five: Possessing financial flexibility 
 
The final guiding condition emerging strongly from the literature is the ability to flexibly 
deploy adequate resource, including finance, time, equipment and skilled personnel to 
achieve optimal healthcare provision (Patel et al., 2012).  
 
In terms of collaborative arrangements, the design of risk-sharing agreements, and new 
models of reimbursement have great potential but also present significant challenge to 
implement, according to Neumann (Neumann et al., 2011). Collaboration requires the 
creation of payment systems that align financial incentives to provide greater value  (Porter 
& Ishrak, 2015), while dealing with barriers to success requires organisations to overcome 
the limited access to financial capital (Kotzbauer & Weeks, 2015b). Value-based 
contracting is grounded in the premise of reducing cost by eliminating inappropriate 
utilization and lowering prices , sharing savings or capturing a portion of the value created 
through lower costs and/or increasing volume through market share gains resulting from 
enhanced value to the customer (Eggbeer et al., 2015). 
 
Carlson et al (2010) identifies the potential benefits of new pricing schemes on improving 
health outcomes in ‘real world’ patients, whilst noting the significant challenges in 
developing these schemes due to factors such as upfront administrative burdens and 
dependency on robust information systems (Carlson et al., 2010). Despite the potential to 
alter the reimbursement and pricing landscape, these barriers may limit the long-term 
impact, and as such Carlson suggests further studies are required to evaluate the 
experiences and impact of schemes and further determine the value in healthcare spending 
realised. Furthermore, in exploring new models to fund innovation, both system and sector 
may need to make changes in their organisational accounting practices and policies. By 
including finance and accounting experts from the outset of partnerships, VBHC 
collaborations will ensure the shaping of any new approaches are compliant with local and 
national policy.     
 
According to Deerberg-Wittram et al., (2017), financial and resource flexibility in the 
context of VBHC, is particularly important from the perspective of the system 
collaborating with medical technology companies. Some medical technology firms have 
the financial flexibility to allow investment of resource into the development of 
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standardized, scalable value-based solutions, that improve outcomes-to-cost ratios in a 
specific domain, for example across a disease care cycle.  
 
However, there is recognition of the requirement to co-create new business and financial 
models which align system and sector initiatives to provide greater value through 
healthcare provision (Porter & Ishrak, 2015). It is also identified again that UK 
Government is encouraging system-sector contractual arrangements over a longer-term 
than is currently practised, but with a greater degree of flexibility (Gov UK, 2017; WAG, 
2018). The proposed longer contractual agreements must be more substantive and 
strategic, rather than being short-term, ad-hoc agreements. The reference to flexibility in 
contractual arrangements is deemed important to (NHS) managers who seek flexibility in 
service provision from the sector (Field & Peck, 2003). Considering this, contractual 
arrangements around system-sector collaborations must be properly negotiated, flexible 
and still offer a satisfactory deal and incentivisation for both parties (Field & Peck, 2003).  
 
The literature described the importance of the development of new financial models for 
Value-Based Pricing (VBP) and risk-sharing agreements where payers (healthcare 
providers) and sector stakeholders agree to link payment for drugs to health outcomes 
through a flexible re-imbursement models (Garrison & Towse, 2017; Robinson et al., 
2018). It is also noted that closer alignment between financial and clinical personnel is 
required to improve care at lower cost through development of performance-based flexible 
reimbursement models and a joint definition of ‘Value’(Carlson et al., 2010; Garrison & 
Towse, 2017).  
 
This represents a potentially appealing reimbursement model which might aid in more 
efficient delivery of new medicines and products, from sector to system, targeted at better 
health outcomes for patients. For this to be realised finance and clinical personnel must 
work to agree on shared language and understanding on what they consider to be ‘value’ 
with respect to value-based pricing and contracting.  This is argued to potentially improve 
care provision in the system and reimburse manufacturers of a new drug, technology or 
product in the sector through flexible performance-based re-imbursement schemes 
(Carlson et al., 2010; Garrison & Towse, 2017; Lee, 2010).  
 
Through such models and schemes, the capture of outcomes and costs associated with the 
care provision from the system and the opportunity for honest appraisals of new evidence 
from ongoing data capture (Lewis, 2019). Health outcome and cost data acquired post 
adoption of new drugs, technologies, innovations and products may also be used to monitor 
any overall changes of efficiencies across a given care pathway and could therefore inform 
investment or disinvestment accordingly (Garrison & Towse, 2017; Lewis, 2019).  
 
It is noteworthy to declare that other conditions were surfaced throughout the literature 
review. These included scalability (Nishtar, 2004); an embedded collaboration champion 
and use of their networks (Wohlin et al., 2012); high degrees of commitment and shared 
vision (Jacobson & Ok Choi, 2008), trust, experience and incentives (Patel et al., 2012); 
time (Nilsson et al., 2017); and policy alignment (Lehoux, Miller, Daudelin, & Denis, 
2017). Although we recognise the relevance of these factors in the extant literature, further 
exploration was omitted from inclusion in this paper as they did not surface in more than 




To close this section, figure one is a diagrammatic representation of the five guiding 
conditions derived from the literature search, showing their relationship to the system and 
sector.   The paper now concludes with the contribution of the work and recommendations 






Figure 1. Guiding conditions required for system sector collaboration for implementation 
of VBHC. 
 
Conclusions and Further Research 
 
The contributions of the paper 
 
This paper has introduced the pressures on the government-funded NHS (Crocker et al., 
2009) and the concept of implementation of VBHC collaboration through the healthcare 
system-life science sector nexus as a mechanism of mitigation against growing challenges. 
The development of VBHC from initial work in the United States has been traced, but it is 
noted that the debate is now gaining increased traction in other geographic contexts, 
particularly the UK and Europe, in response to an escalating acknowledgement that current 




With government and policy drive towards closer alignment of sector and system, the UK 
context offers a comparatively supportive policy context for collaboration (Crocker et al., 
2009; Ferlie & McGivern, 2003),  as the findings of the paper suggest.  It is proposed that 
the five GCs surfaced in this paper are fundamental for the successful implementation of 
VBHC through system-sector collaboration. 
 
The strategic drivers of this increased attention were discussed, including economic factors 
and demographics. Potential barriers such as a lack of societal trust of corporate 
involvement in the UK NHS were briefly considered, but the main focus of this paper is 
the current lack of large-scale operational collaboration between the healthcare industry 
and the healthcare systems, outside of the research environment. It is evident from the 
review underpinning this paper that there are few examples of collaborations by an industry 
and healthcare system partner that have been proven to have achieved the balance of 
service delivery optimisation  with constrained resources and adherence to performance 
measures requires in one region and adopted across a healthcare system(s) (Chahal & 
Eldabi, 2011).  
 
It is noted that Porter and Lee have proposed components of a strategy “…for moving to a 
high-value healthcare delivery system” (Porter & Lee, 2013, p. 52).  However, while their 
proposition should be noted, the guiding conditions set out here have drawn insights from 
a broad range of literature incorporating research from contexts outside of the US.  
Moreover, the authors concur with Gray, who emphasises “…the important difference in 
the use of the term value in the American literature” (Gray, 2017b, p. 1). 
 
The conclusions from this exploratory work shows that while an accepted model of 
collaboration does not yet exist, the literature suggests determinants that can enable 
successful collaborations.  It is acknowledged that the healthcare landscape is complex and 
that these five guiding conditions represent an abstraction of that reality.  However, as a 
framework to help make sense of this complexity it is proposed that they offer a starting 
point for analysis and a potentially useful guide to further research. 
 
It is argued that this paper has made a constructive contribution to the field by further 
insight beyond the valuable work undertaken in the United States, to include more research 
from the United Kingdom and Europe.  In this way it is hoped to extend our understanding 
of VBHC and in particular the way the notion of ‘value’ is used in differing contexts. 
 
More broadly, the review of the literature convinces that a collaborative approach is crucial 
for the necessary paradigm shift in the way that healthcare funding is approached and the 
dominant business models in the healthcare industry.  Ultimately the aim of this research 
agenda is to contribute to practice and policy; to influence these for the betterment of 
patient care in the complex context imposed by the strategic drivers discussed in the 
introductory section.  However, this depends on the execution of a coherent and focused 




Recommendations for future research  
 
While understanding of VBHC is growing, it remains comparatively under-researched as 
an alternative paradigm for healthcare.  The context is self-evidently complex, and 
therefore one of the key objectives of this paper is to propose a coherent programme of 
further research on VBHC.   
 
The next stage of the research agenda requires a focus on the empirical assessment of the 
proposed guiding conditions discussed in this paper.  In parallel, the analysis of the 
literature on VBHC needs to remain an ongoing project, in light of the growing body of 
research and the increasing demand for alternative approaches from those engaged in 
healthcare from a practical perspective. 
The literature-derived GCs should now be evaluated empirically for their perceived 
practical importance to key participants, or potential participants in system-sector 
collaboration toward VBHC.  
 
Continuing exploration to build on the work of this paper should employ multiple methods 
of data gathering and analysis.  Initially it is proposed that in-depth interviews with key 
respondents are used to obtain rich data on perceptions of the significance of the guiding 
conditions.  This data could then be analysed using techniques such as content analysis and 
interpretive structural modelling (ISM) to help articulate the complexity of the 
relationships in research context more clearly.  Further larger-scale studies employing 
elements of quantitative analysis should follow this initial ‘theory building’ phase, which 
will allow well founded proposals for practice to be made.  The future contribution to 
practice should include recommendations on the role of government and policy on 
facilitating the conditions for collaboration in VBHC 
 
The empirical evaluation of the five guiding conditions may confirm these themes from 
the literature.  However, it will be important to remain sensitive to further themes that may 
emerge from the data such as those previously highlighted, but omitted from the scope for 
further exploration, in this study.  In addition, it may be possible to begin to build increased 
understanding of the relative importance of the guiding conditions, and how the 
relationships between them may be explored. 
 
Ultimately, the objective of the research agenda should be the development of a system-
sector collaborative model to inform alignment of industry, the NHS and academia to 
innovate in pursuit of improved patient and public outcomes. Here, academia can arguably 
be utilised as an un-biased broker for research and knowledge transfer. Following the 
elucidation of a five importance guiding conditions, the commissioning of further larger-
scale studies through engagement with system and sector stakeholders should be sought to 
provide an evaluation for the current working model and identify barriers/challenges and 
opportunities for improvement. Thus, describing an enhanced model/framework for 
improving the current and future healthcare-industrial collaborations through the lens of 
VBHC. 
 
As stated earlier, it is acknowledged that the list of five guiding conditions could be 
criticised as being overly reductive.  It is axiomatic that these will be interlinked in complex 
ways.  For this reason, one strand of conceptual development should be to develop an 
overarching perspective that allows for an understanding of this complexity while offering 
shared principles for action across the system-sector collaborative ecosystem.  It is 
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suggested tentatively that the concept of ‘strategic agility’ (see for example Doz and 
Kosonen, 2010) could offer a useful lens through which to consider a shared approach to 
system-sector collaboration.  Essentially, organisations that consider themselves 
strategically agility retain the ability to continuously adjust strategic direction and develop 
innovative ways to create value while retaining an overall direction or mission (Weber & 
Tarba, 2014).  The underlying ‘meta-capabilities’ demanded by strategic agility bear strong 
resemblance to many of the characteristics of the guiding conditions identified here.  While 
this is a concept that has been applied largely to the private sector, it has already been used 
to examine strategic alliances and may offer a useful holistic construct for multi-
stakeholder collaborations. 
 
In summary, whichever lens is employed to examine the VBHC landscape, the complexity 
of the collaborative ecosystem needs to be acknowledged.  Despite this, it is proposed here 
that the five guiding conditions revealed by this evaluation of the developing literature on 
VBHC offer a practical and constructive framework that has the potential to inform both 




Akerman, C., & Stowell, C. (2015). Measuring outcomes: the key to Value-based health 
care.  Harv Bus Webinar . 
Aneurin Bevan University Health Board. (2019). Value Based Healthcare: Learning 
from practice. 
AstraZeneca. (2018). AstraZeneca Collaboration with Leeds Teaching Hospitals NHS 
Trust. 
Bacon, E., Williams, M. D., & Davies, G. H. (2019). Recipes for success: Conditions for 
knowledge transfer across open innovation ecosystems. International Journal of 
Information Management, 49, 377–387. 
https://doi.org/10.1016/j.ijinfomgt.2019.07.012 
Beck, E., Craing, A., Beeson, J., Bourn, S., Goodloe, J., Moy, H. P., … White, L. (2012). 
Mobile Integrated Healthcare Practice : A Healthcare Delivery Strategy to Improve 
Access, Outcomes, and Value. 
Berwick, D. M., & Hackbarth, A. D. (2012). Eliminating Waste in US Health Care. 
JAMA, 307(14), 1513–1516. https://doi.org/10.1001/jama.2012.362 
Carlson, J. J., Sullivan, S. D., Garrison, L. P., Neumann, P. J., & Veenstra, D. L. (2010). 
Linking payment to health outcomes: A taxonomy and examination of performance-
based reimbursement schemes between healthcare payers and manufacturers. Health 
Policy, 96(3), 179–190. https://doi.org/10.1016/j.healthpol.2010.02.005 
Chahal, K., & Eldabi, T. (2011). Hybrid simulation and modes of governance in UK 
healthcare. Transforming Government: People, Process and Policy, 5(2), 143–154. 
https://doi.org/10.1108/17506161111131177 
Chapman, A. (2014). The Impact of Reliance on Private Sector Health Services on the 
Right to Health. Health and Human Rights Journal , 16(1). 
Charlesworth, A., Johnson, P., Firth, Z., Gershlick, B., Watt, T., Kelly, E., … Zaranko, 
B. (2018). Securing the future: funding health and social care to the 2030. 
Retrieved from http://www.ifs.org.uk 
Charlesworth, Anita, Charlesworth, A., Watt, T., & Johnson, P. (2018). Securing the 
future : funding health and social care to the 2030. In Institute of Fiscal Studies. 
Collins, B. (2018). Adoption and spread of innovation in the NHS. Retrieved October 4, 




Crocker, T., Johnson, O., & King, S. (2009). The suitability of care pathways for 
integrating processes and information systems in healthcare. Transforming 
Government: People, Process and Policy, 3(3), 289–301. 
https://doi.org/10.1108/17506160910979379 
Damberg, C. L., Sorbero, M. E., Lovejoy, S. L., Martsolf, G. R., Raaen, L., & Mandel, D. 
(2014). Measuring Success in Health Care Value-Based Purchasing Programs: 
Findings from an Environmental Scan, Literature Review, and Expert Panel 
Discussions. Rand Health Quarterly, 4(3), 9. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/28083347 
Deerberg-Wittram, M., Lüdtke, L., Lavoie, B., Schroer, D., & Gerecke, G. (2017). Why 
Every Medtech Company Needs a Value-Based Strategy. BCG. Retrieved from 
https://www.bcg.com/publications/2017/health-care-why-every-medtech-company-
needs-value-based-strategy.aspx 




Deloitte. (2019). Patient access to innovative medicines in Europe: A collaborative and 
value based approach. (January), 40. Retrieved from 
https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-
care/deloitte-uk-patient-access-to-innovative-medicine-in-europe.pdf 
Doyle, J. (2011). The effect of comparative effectiveness research on drug development 
innovation: a 360° value appraisal. Dove Press, 1, 27–34. 
https://doi.org/https://doi.org/10.2147/CER.S15478 
Eggbeer, B., Sears, K., & Homer, K. (2015). Finding the ‘sweet spot’ in value-based 
contracts. Healthcare Financial Management, 69(8), 48–57. 
EIU. (2016a). Healthcare and Pharmaceuticals. In The Economist Intelligence Unit. 
EIU. (2016b). Value-based healthcare: A global assessment. The Economist Intelligence 
Unit: Findings and Methodology., 1–31. Retrieved from 
http://vbhcglobalassessment.eiu.com/wp-
content/uploads/sites/27/2016/09/EIU_Medtronic_Findings-and-Methodology.pdf 
European Commission. (2019). Defining Value In “Value-Based Healthcare” : Expert 
Panel on effective ways of investing in Health (EXPH). 
https://doi.org/10.2875/872343 
EXPH. (2019). Expert panel on effective ways of investing in health. Opinion on 
Defining value in “value-based healthcare.” In European Commission. 
https://doi.org/10.2875/35471 
Ferlie, E., & McGivern, G. (2003). Relationships between health care organisations: a 




Field, J. E., & Peck, E. (2003). Public–private partnerships in healthcare: the managers’ 
perspective. Health & Social Care in the Community, 11(6), 494–501. 
https://doi.org/10.1046/j.1365-2524.2003.00455.x 
Ford, E. W., & Hughes, J. A. (2007). A Collaborative Product Commerce Approach to 
Value-based Health Plan Purchasing. Supply Chain Management: An International 
Journal., 12(1), 32–41. 
Gabriel, L., Fellow, D., Casey, J., Delivery, D. P., Palmer, M. C., Outcomes, P., … John, 
21 
 
P. (2018). Value Based Healthcare analysis of joint replacement surgery for 
primary hip osteoarthritis Why take on a Value Based Healthcare transformation 
Traditional PROMS vs patient-centred outcomes Calculating value : understanding 
outcomes that matter to patient. 
Garrison, L. P., & Towse, A. (2017). Value-Based Pricing and Reimbursement in 
Personalised Healthcare: Introduction to the Basic Health Economics. Journal of 
Personalized Medicine, 7(3), 10. https://doi.org/10.3390/jpm7030010 
Gerecke, G., Clawson, J., & Verboben, Y. (2015). Procurement: The Unexpected Driver 
of Value-Based Health Care. BCG Report. 
Gov UK: Office For Life Sciences (OLS). (2017). Strength and Opportunity 2017: The 
landscape of the medical technology and biopharmaceutical sectors in the UK. 
Gov UK. (2016). Accelerated Access Review: Final Report: Review of innovative 
medicines and medical technologies. Retrieved from 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/5650
72/AAR_final.pdf 
Gov UK. (2017). Life sciences: Industrial Strategy. Retrieved from 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attach
ment_data/file/650447/LifeSciencesIndustrialStrategy_acc2.pdf 
Gov UK. (2018a). Industrial Strategy: Life Sciences Sector Deal 2. 
Gov UK. (2018b). New Life Sciences Sector Deal opens doors to transform treatments 
and save lives. Retrieved January 29, 2020, from 
https://www.gov.uk/government/speeches/new-life-sciences-sector-deal-opens-
doors-to-transform-treatments-and-save-lives 
Gray, M. (2017). Value based healthcare. BMJ, j437. https://doi.org/10.1136/bmj.j437 
Handke, B., Gaffney, J., & Oberoi, N. (2017). Value-Based Healthcare: An Industry 
Perspective. Vein Magazine. 
Hara, N., Solomon, P., Kim, S.-L., & Sonnenwald, D. H. (2003). An emerging view of 
scientific collaboration: Scientists’ perspectives on collaboration and factors that 
impact collaboration. Journal of the American Society for Information Science and 
Technology, 54(10), 952–965. https://doi.org/10.1002/asi.10291 
Hardin, L., Kilian, A., & Murphy, E. (2017). Bundled Payments for Care Improvement: 
Preparing for the Medical Diagnosis-Related Groups. The Journal of Nursing 
Administration, 47(6), 313–319. https://doi.org/10.1097/NNA.0000000000000492 
Haywood, T. (2010). The cost of confusion: healthcare reform and value-based 
purchasing. Healthcare Financial Management, 64(10), 44-49. 
Horne, F., Katz, G., & Seidman, G. (2019). Four lessons for a successful switch to value-
based healthcare. Retrieved from https://www.weforum.org/agenda/2019/03/four-
lessons-for-successful-healthcare-transformation/ 
Hu, P., Chau, P., & Sheng, O. (2000). Investigation of Factors Affecting Healthcare 
Organizations’ Adoption of Telemedicine Technology. 
https://doi.org/10.1109/HICSS.2000.926799 
Hurh, J., Ko, Y.-H., & Lee, S.-S. (2017). Value-based healthcare: Prerequisites and 
suggestions for full-fledged implementation in the Republic of Korea. Journal of 
Korean Medical Association, 60, 826. https://doi.org/10.5124/jkma.2017.60.10.826 
ICHOM. (2015). What Matters Most: Patient Outcomes and the Transformation of 
Health Care. International Consortium for Health Outcomes Measurement. 
Jacobson, C., & Ok Choi, S. (2008). Success factors: public works and public‐private 
partnerships. International Journal of Public Sector Management, 21(6), 637–657. 
https://doi.org/10.1108/09513550810896514 
Jönsson, B. (2009). Ten arguments for a societal perspective in the economic evaluation 
22 
 
of medical innovations. The European Journal of Health Economics, 10(4), 357–
359. https://doi.org/10.1007/s10198-009-0173-2 
Kaplan, R. M., & Babad, Y. M. (2011). Balancing influence between actors in healthcare 
decision making. BMC Health Services Research, 11(1), 85. 
https://doi.org/10.1186/1472-6963-11-85 
Kaplan, R., & Porter, M. (2011). How to solve the cost crisis in health care. Harvard 
Business Reviews, 54, 56–61. 
Kavanagh, K. T., Cimiotti, J. P., Abusalem, S., & Coty, M.-B. (2012). Moving healthcare 
quality forward with nursing-sensitive value-based purchasing. Journal of Nursing 
Scholarship : An Official Publication of Sigma Theta Tau International Honor 
Society of Nursing, 44(4), 385–395. https://doi.org/10.1111/j.1547-
5069.2012.01469.x 
Keel, G., Savage, C., Rafiq, M., & Mazzocato, P. (2017). Time-driven activity-based 
costing in health care: A systematic review of the literature. Health Policy, 121(7), 
755–763. https://doi.org/https://doi.org/10.1016/j.healthpol.2017.04.013 
Kotzbauer, G., & Weeks, W. (2015a). Developing the organizational competencies 
needed in value-based payment systems. Healthcare Financial Management, 69(7), 
76–77. 
Kotzbauer, G., & Weeks, W. B. (2015b). Developing the organizational competencies 
needed in value-based payment systems. Healthcare Financial Management, 67(7), 
76–77. Retrieved from 
https://search.proquest.com/docview/1699223103?accountid=14680 
Kuchenreuther, M. J., & Sackman, J. E. (2015). Value-Based Healthcare in the: United 
Kingdom. Pharmaceutical Technology, 39(1). 
Lee, T. H. (2010). Putting the Value Framework to Work. New England Journal of 
Medicine, 363(26), 2481–2483. https://doi.org/10.1056/NEJMp1013111 
Leemore S. Dafny, Ph.D., Christopher J. Ody, Ph.D., and Matthew A. Schmitt, P. D. 
(2016). Undermining Value-Based Purchasing — Lessons from the Pharmaceutical 
Industry. New England Journal of Medicine, 1–3. 
Lehoux, P., Miller, F. A., Daudelin, G., & Denis, J.-L. (2017). Providing Value to New 
Health Technology: The Early Contribution of Entrepreneurs, Investors, and 
Regulatory Agencies. International Journal of Health Policy and Management, 
6(9), 509–518. https://doi.org/10.15171/ijhpm.2017.11 
Lewis, S. (2019). Value-based healthcare – meeting the evolving needs. Australian 
Health Review, 43(5), 485. https://doi.org/http://dx.doi.org/10.1071/AHv43n5_ED 
Malik, R. F., Hilders, C. G. J. M., & Scheele, F. (2018). Do ‘physicians in the lead’ 
support a holistic healthcare delivery approach? A qualitative analysis of 
stakeholders’ perspectives. BMJ Open, 8(7), e020739. 
https://doi.org/10.1136/bmjopen-2017-020739 
Martschinke, B., & Traut, A. (2016). Early Benefit Assessment Of Drugs And The 
Value-Based Healthcare Concept – A Qualitative Inquiry Within The 
Pharmaceutical Industry. Value in Health, 19(7), A448. 
https://doi.org/10.1016/j.jval.2016.09.589 
Medtronic. (2016). Medtronic Focus on Value-based Healthcare Increases Worldwide. 
Key Event Takeaways, 1–2. 
Miller, D. (2012). Value-Based Pricing: Examples of Healthcare System Reforms from 
the UK and US and Implications for Industry. Pharmaceutical Medicine, 26(4), 
217–222. https://doi.org/DOI: 10.2165/11633860-000000000-00000, 
Mills, M., & Kanavos, P. (2019). Do pharmaceutical budgets deliver financial 




Moxham, J. (2018). The Vital 5. Retrieved October 3, 2019, from The Kings Trust 
website: https://www.kingshealthpartners.org/latest/1954-the-vital-5 
Neumann, P. J., Chambers, J. D., Simon, F., & Meckley, L. M. (2011). Risk-Sharing 
Arrangements That Link Payment For Drugs To Health Outcomes Are Proving 
Hard To Implement. Health Affairs, 30(12), 2329–2337. 
https://doi.org/10.1377/hlthaff.2010.1147 
Neville, S. (2019). NHS and Life Science Sector Failing to Work Together. Financial 
Times. 
Nilsson, K., Bååthe, F., Andersson, A. E., Wikström, E., & Sandoff, M. (2017). 
Experiences from implementing value-based healthcare at a Swedish University 
Hospital – a longitudinal interview study. BMC Health Services Research, 17(1), 
169. https://doi.org/10.1186/s12913-017-2104-8 
Nishtar, S. (2004). Public - private “partnerships” in health - a global call to action. 
Health Research Policy and Systems, 2(1), 5. https://doi.org/10.1186/1478-4505-2-5 
OECD. (2017). Tackling Wasteful Spending on Health. 
https://doi.org/https://doi.org/10.1787/9789264266414-en. 
Patel, H., Pettitt, M., & Wilson, J. R. (2012). Factors of collaborative working: A 
framework for a collaboration model. Applied Ergonomics, 43(1), 1–26. 
https://doi.org/https://doi.org/10.1016/j.apergo.2011.04.009 
Pilemalm, S., Lindgren, I., & Ramsell, E. (2016). Emerging forms of inter-organizational 
and cross-sector collaborations in e-government initiatives: Implications for 
participative development of information systems. Transforming Government: 
People, Process and Policy, 10(4), 605–636. https://doi.org/10.1108/TG-12-2015-
0055 
Porter, M. E., & Ishrak, O. (2015). The State of Adoption in Value-Based Health Care. 
New England Journal of Medicine Report, 1–9. 
Porter, M. E., & Lee, T. H. (2013). The Strategy That Will Fix Health Care. Harvard 
Business Review. 
Porter, M. E., Pabo, E. A., & Lee, T. H. (2013). Redesigning Primary Care: A Strategic 
Vision To Improve Value By Organizing Around Patients’ Needs. Health Affairs, 
32(3), 516–525. https://doi.org/10.1377/hlthaff.2012.0961 
Porter, M. E., & Teisberg, E. (2006). Redefining Health Care: Creating Value-Based 
Competition on Results. Harvard Business School Press. 
Robinson, J. C., Howell, S., & Pearson, S. D. (2018). Value-Based Pricing and Patient 
Access for Specialty Drugs. JAMA, 319(21), 2169–2170. 
https://doi.org/10.1001/jama.2018.5367 
TheKingsFund. (2019). The NHS long-term plan explained. Retrieved October 3, 2019, 
from https://www.kingsfund.org.uk/publications/nhs-long-term-plan-explained 
VBHC Center Europe. (2019). Pursuing the next steps of VBHC implementation: from 
good to great patient value Looking back to move forward. Retrieved from 
www.thedecisioninstitute.org 
Verbeek, X., & Lord, W. (2007). The care cycle: an overview. Medicamundi, 51(1), 40–
47. 
WAG. (2018). Welsh Government | A Healthier Wales: our Plan for Health and Social 




Wang, P. S., Ulbricht, C. M., & Schoenbaum, M. (2009). Improving Mental Health 
24 
 
Treatments Through Comparative Effectiveness Research. Health Affairs, 28(3), 
783–791. https://doi.org/10.1377/hlthaff.28.3.783 
WHO. (2009). WHO Guidelines on Hand Hygiene in Health Care: First Global Patient 
Safety Challenge Clean Care Is Safer Care. Geneva: World Health Organization. 
Retrieved January 27, 2020, from 
https://www.ncbi.nlm.nih.gov/books/NBK144006/ 
Wohlin, C., Aurum, A., Angelis, L., Phillips, L., Dittrich, Y., Gorschek, T.,  Winter, J. 
(2012). The Success Factors Powering Industry-Academia Collaboration. IEEE 
Software, 29(2), 67–73. https://doi.org/10.1109/MS.2011.92 
Young, D., Barrett, D., Kenagy, J., Pinakiewicz, D., & McCarthy, S. (2001). Value-
Based Partnering in Healthcare: A Framework for Analysis//Practitioner application. 
Journal of Healthcare Management / American College of Healthcare Executives, 
46, 112–132; discussion 133. https://doi.org/10.1097/00115514-200103000-00007 
Zelmer, J. (2018). Identifying the Most Promising Opportunities for Value-Based 
Healthcare: Design Day Strategic Outcomes Summary. 
 
 
